# A Long-term Trial of EB-1020 in Adult Patients With ADHD

> **NCT06926829** · PHASE3 · RECRUITING · sponsor: **Otsuka Pharmaceutical Co., Ltd.** · enrollment: 180 (estimated)

## Conditions studied

- Attention Deficit Hyperactivity Disorder (ADHD)

## Interventions

- **DRUG:** EB-1020 (Centanafadine) 164.4 mg
- **DRUG:** EB-1020 (Centanafadine) 328.8 mg

## Key facts

- **NCT ID:** NCT06926829
- **Lead sponsor:** Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-25
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2025-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06926829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06926829, "A Long-term Trial of EB-1020 in Adult Patients With ADHD". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT06926829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*